Correlation between ApoE and SLCO1B1 gene polymorphisms and blood lipids and liver function of patients with dyslipidemia after atorvastatin lipid-lowering therapy
Objective To investigate the association of ApoE and SLCO1B1 polymorphism with lipid and liver function in patients with dyslipidemia after lipid-lowering with atorvastatin.Methods A total of 128 patients with dyslipidemia in Cangzhou People's Hospital from January 2020 to September 2023 were collected.The patient received at least 4 weeks of atorvastatin therapy.ApoE genes,SLCO1B1 genes,blood lipids,and liver function indicators were detected.The relationship between their genotype and lipid-lowering efficacy,as well as liver function indicators was evaluate.Results After atorvastatin treatment,the levels of TG and HDL-C of ApoE gene phenotype in E2 group,the levels of TC,HDL-C,LDL-C,and LDL-C in E3 group,and the levels of HDL-C in E4 group were improved compared with before treatment,and the difference was statistically significant(P＜0.05).After treatment,there was no statistically significant difference in ALT among ApoE gene phenotype groups,while only the difference in GGT of E3 group was statistically significant(P＜0.05).After atorvastatin therapy,TC,TG,HDL-C,and LDL-C of SLCO1B1 gene phenotype Ⅰ improved compared to before treatment,while HDL-C of SLCO1B1 gene phenotype Ⅱ improved compared to before treatment,with statistical significance(P＜0.05).After treatment,there was no statistically significant difference in ALT and GGT among the SLCO1B1 gene phenotype groups.Conclusion In the clinical application of statins,the lipid-lowering efficacy can be evaluated by detecting APOE and SLCO1B1 gene polymorphisms,and the individualized use of atorvastatin can be realized.
atorvastatindyslipidemiaApoE geneSLCO1B1 geneblood lipidliver function
NETL
NSTL
万方数据
